Results 101 to 110 of about 4,992,798 (298)

Modern Pharmacotherapy of Parkinson´s disease

open access: yes, 2014
This thesis makes an effort to cover the most commonly used agents in the treatment of Parkinson´s disease as well as tracing out modern pharmacological therapeutic methods used in this disease.általános orvosangolegységes ...
Bhatti, Mohammad Arslan
core  

Differential sialylation of serpin A1 in the early diagnosis of Parkinson's disease dementia. [PDF]

open access: yes, 2012
The prevalence of Parkinson's disease (PD) increases with age. Up to 50% of PD show cognitive decline in terms of a mild cognitive impairment already in early stages that predict the development of dementia, which can occur in up to 80% of PD patients ...
Hans A Kretzschmar   +72 more
core   +1 more source

Natural Frequencies of Levodopa‐Induced Dyskinesia in Parkinson's Disease

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objectives Abnormal involuntary movements, known as dyskinesias, are common complications of levodopa treatment in patients with Parkinson's disease and can significantly impair quality of life. The underlying pathophysiology remains unclear, and current therapeutic options are limited.
Ioannis U. Isaias   +3 more
wiley   +1 more source

Fatigue, mood disorders and sleep problems in patients with Parkinson's disease [PDF]

open access: yes, 2008
De Ziekte van Parkinson (PD) is een langzaam progressieve ziekte gekarakteriseerd door zijn motorische en meer recentelijk herkende nietmotorische verschijnselen. Dit proefschrift richt zich op vermoeidheid, slaap problemen en stemmingsstoornissen, op de
Havlikova, Eva, Havlikova, Eva,
core   +15 more sources

Global Rather Than Vertical‐Selective Saccadic Abnormalities in Progressive Supranuclear Palsy

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To test whether vertical saccades are preferentially affected in Progressive Supranuclear Palsy (PSP). Methods PSP patients (n = 24) were compared to age‐matched controls (n = 94) and two degenerative groups (Alzheimer's disease, n = 20; Lewy body disease, n = 50).
Duy Duan Nguyen   +6 more
wiley   +1 more source

Metabolic Parkinson’s disease

open access: yesFrontiers in Aging Neuroscience
Parkinson’s disease (PD) is a neurodegenerative disorder primarily characterized by the loss of dopaminergic neurons in the substantia nigra. While most cases are sporadic, there is growing evidence of a link between PD and metabolic dysfunctions such as
Federica Invernizzi   +13 more
doaj   +1 more source

Vascular Disease, Non‐Steroidal Anti‐Inflammatory Drugs and Risk of Parkinson's Disease

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objectives A history of vascular disease has been shown to be associated with an increased risk of Parkinson's disease, but this may be due to reverse causation. In addition, non‐steroidal anti‐inflammatory drugs are thought to reduce Parkinson's disease risk, but evidence is inconsistent and confounding by prior vascular disease is possible ...
Clare Wotton   +4 more
wiley   +1 more source

A lesão dopaminérgica como modelo de estágio pré-motor da doença de Parkinson: efeitos do antagonismo do receptor CB1 [PDF]

open access: yes, 2012
Tese (doutorado) - Universidade Federal de Santa Catarina, Centro de Ciências Biológicas, Programa de Pós-Graduação em Farmacologia, Florianópolis, 2010Além dos sinais motores clássicos, a doença de Parkinson é caracterizada por déficits cognitivos e ...
Tadaiesky, Meigy Tavares
core  

Driving in Parkinson Disease

open access: yes, 2020
Driving is impaired in most patients with Parkinson disease because of motor, cognitive, and visual dysfunction. Driving impairments in Parkinson disease may increase the risk of crashes and result in early driving cessation with loss of independence ...
Devos, Hannes   +2 more
core   +1 more source

CSF concentrations of cAMP and cGMP are lower in patients with Creutzfeldt-Jakob disease but not Parkinson's disease and amyotrophic lateral sclerosis. [PDF]

open access: yes, 2012
The cyclic nucleotides cyclic adenosine-3',5'-monophosphate (cAMP) and cyclic guanosine-3',5'-monophosphate (cGMP) are important second messengers and are potential biomarkers for Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS) and ...
Oeckl, Patrick   +23 more
core   +1 more source

Home - About - Disclaimer - Privacy